Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

Published:2020-12-01 Issue:5 Volume:27 Page:1256-1266
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

de Haan Rosemarie,van den Heuvel Michel M.^ORCID,van Diessen Judi,Peulen Heike M.U.,van Werkhoven Erik^ORCID,de Langen Adrianus J.,Lalezari Ferry,Pluim Dick,Verwijs-Janssen Manon,Vens Conchita^ORCID,Schellens Jan H.M.,Steeghs Neeltje,Verheij Marcel^ORCID,van Triest Baukelien

Funder

AstraZeneca

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer;Frontiers in Oncology;2024-08-02

2. Use of Radiation Therapy for Ataxia-Telangiectasia Mutated (ATM)-Mutation Metastatic Renal Cell Carcinoma: A Case Report;Cureus;2024-07-17

3. The first real-world study on the role of carbon ion radiotherapy for oligo-metastatic, persistent, or recurrent (MPR) ovarian/fallopian tube cancer;Clinical and Translational Radiation Oncology;2024-07

4. Strahlentherapie und molekular zielgerichtete Therapie – alles gezielt?;Die Onkologie;2024-05-09

5. Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial;International Journal of Radiation Oncology*Biology*Physics;2024-04